[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Bristol-Myers Squibb Stock: Analyst Estimates & Ratings

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. With a market cap of $129.9 billion, the company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.

Shares of BMY have rallied the broader market over the past year, surging 33.9% compared to the S&P 500 Index’s ($SPX) 16.3% surge. Moreover, in 2026, the stock has risen by nearly 17.9%, outpacing the SPX’s 8.5% gain.        

Fundamentals

See More
  • Market Capitalization, $K 129,875,720
  • Shares Outstanding, K 2,042,071
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,521 M
  • EBITDA $ 16,532 M
  • 60-Month Beta 0.23
  • Price/Sales 2.65
  • Price/Cash Flow 7.69
  • Price/Book 6.36

Options Overview Details

View History
  • Implied Volatility 33.44% (+1.39%)
  • Historical Volatility 29.75%
  • IV Percentile 82%
  • IV Rank 63.42%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 2) 2.31 (3.66%)
  • Put/Call Vol Ratio 0.98
  • Today's Volume 9,646
  • Volume Avg (30-Day) 25,749
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 640,420
  • Open Int (30-Day) 610,748
  • Expected Range 60.92 to 65.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.59
  • Number of Estimates 8
  • High Estimate $1.61
  • Low Estimate $1.52
  • Prior Year $1.46
  • Growth Rate Est. (year over year) +8.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.30 +13.13%
on 07/01/26
64.96 -1.96%
on 07/28/26
+5.13 (+8.76%)
since 06/29/26
3-Month
53.44 +19.18%
on 06/18/26
64.96 -1.96%
on 07/28/26
+6.10 (+10.59%)
since 04/29/26
52-Week
42.52 +49.79%
on 10/29/25
64.96 -1.96%
on 07/28/26
+16.83 (+35.92%)
since 07/29/25

Most Recent Stories

More News
Bristol-Myers Squibb Stock: Analyst Estimates & Ratings

Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

XLV : 167.78 (+0.31%)
$SPX : 7,356.55 (-0.97%)
BMY : 63.77 (+0.27%)
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

BMY : 63.77 (+0.27%)
Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now

As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.

MO : 75.61 (+1.06%)
AEP : 131.99 (-0.77%)
BMY : 63.77 (+0.27%)
3 Healthcare Stocks We Keep Off Our Radar

3 Healthcare Stocks We Keep Off Our Radar

CHE : 535.83 (+3.52%)
VTRS : 17.85 (-0.06%)
BMY : 63.77 (+0.27%)
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

Expanded collaboration gives BMS the most advanced and most energy-efficient NVIDIA infrastructure in life sciences BMS will deploy NVIDIA DGX Vera Rubin NVL72 systems...

BMY : 63.77 (+0.27%)
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Application based on results from SUCCESSOR-2 trial showing oral CELMoD mezigdomide in combination with carfilzomib and dexamethasone significantly improved progression-free survival vs. standard of care...

BMY : 63.77 (+0.27%)
Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect

Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.

XLV : 167.78 (+0.31%)
$SPX : 7,356.55 (-0.97%)
BMY : 63.77 (+0.27%)
2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds

2 Cash-Producing Stocks Worth Investigating and 1 Facing Headwinds

LMB : 68.28 (-5.81%)
MSA : 175.00 (-2.63%)
BMY : 63.77 (+0.27%)
3 Unpopular Stocks with Questionable Fundamentals

3 Unpopular Stocks with Questionable Fundamentals

WAL : 81.54 (-2.52%)
MAS : 72.42 (-11.26%)
BMY : 63.77 (+0.27%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 37.12 (-1.85%)
AZN : 174.46 (+1.15%)
MRK : 131.78 (-0.03%)
GILD : 133.89 (-0.32%)
TEM : 41.55 (-3.15%)
GSK : 53.12 (-1.10%)
ARKK : 70.62 (-2.53%)
BMY : 63.77 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 66.41
2nd Resistance Point 65.69
1st Resistance Point 64.64
Last Price 63.77
1st Support Level 62.88
2nd Support Level 62.16
3rd Support Level 61.11

See More

52-Week High 64.96
Last Price 63.77
Fibonacci 61.8% 56.39
Fibonacci 50% 53.74
Fibonacci 38.2% 51.09
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.